A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer - Concepedia

Concepedia

Publication | Open Access

A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

DOI Full Paper Access

102

Citations

10

References

2012

Year

Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

Abstract

The results suggest that a weekly dose of T-DM1 2.4 mg/kg has antitumor activity and is well tolerated in patients with HER2-positive metastatic breast cancer.

References

	Year	Citations

Page 1